The "Therapeutic Psilocybin Act" (HB 1796-FN) establishes a regulated framework for the medical use of psilocybin in clinical settings to treat conditions such as major treatment-resistant depression, PTSD, and substance use disorders. It creates Chapter 126-XX, which includes definitions, provisions, and the formation of a psilocybin production establishment licensing board within the Department of Health and Human Services. This board will oversee the licensing of qualified providers who can recommend and administer psilocybin. Key provisions include the establishment of a medical psilocybin program, legal protections for participants, and the exemption of FDA-approved psilocybin products from certain regulations. The bill also emphasizes the importance of collaboration with stakeholders to develop best practices and potentially expand the program to include other therapeutic psychedelics.

The bill outlines the requirements for psilocybin production establishments, including licensing processes, operational standards, and inventory control measures. It mandates that individuals must obtain a license to operate such facilities and prohibits licenses for those with felony drug distribution convictions or under 21 years of age. Additionally, it establishes a Therapeutic Psilocybin Treatment Fund to support the program financially and includes provisions for data collection to assess efficacy while maintaining patient confidentiality. The Department of Health is tasked with overseeing the program, ensuring compliance, and reporting on its effectiveness. The act is set to take effect on January 1, 2027, and includes enforcement provisions for violations, as well as a study on the use of other psychedelic compounds for medical treatment.

Statutes affected:
Introduced: 6:12
HB1796 text: 6:12